Document Detail


Alopecia areata: topical immunotherapy treatment with diphencyprone.
MedLine Citation:
PMID:  18005118     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND Topical immunotherapy with diphencyprone (DPCP) is considered the most effective treatment of alopecia areata (AA). OBJECTIVE: To assess the efficacy of DPCP in the treatment of extensive or long-lasting AA in Greek patients. METHODS: Sixty-four patients with extensive and/or long-lasting AA were sensitized with 2% diphencyprone. During each weekly subsequent visit, patients were treated with gradually denser concentrations adjusted in order to maintain erythema and itch on the patient's scalp for 48 h. Patients' hair re-growth was evaluated every 3 months for 2 years. RESULTS: Forty-five patients responded among the 54 completing therapy (83.3%). Initial response was observed 3.48 +/- 1.05 months after the initial treatment. Twenty patients among the responders achieved a grade 4 response, 15 patients achieved grade 3, 9 patients achieved grade 2, and 1 patient achieved a grade 1 response. The mean duration of treatment until maximum response was 6.14 +/- 1.48 months. Thirty-one patients (68.9%) had a relapse during follow-up and were treated again. The only adverse event among patients completing therapy was contact dermatitis of the face or neck (9 of 54) that resolved after topical corticosteroid application within 7 days. Statistical analysis did not establish any association among duration of AA, age, gender, atopic diathesis, nail involvement and presence of thyroid antibodies with response to treatment. CONCLUSION: Treatment of Greek patients with AA with diphencyprone presents high response rates similar to those reported by previous studies. The treatment is adequately tolerated by most of the patients, and they are willing to repeat it in cases of relapse.
Authors:
G Avgerinou; S Gregoriou; D Rigopoulos; A Stratigos; D Kalogeromitros; A Katsambas
Related Documents :
20479298 - Morphologic features and natural history of scalp nevi in children.
10066958 - Pronounced perifollicular lymphocytic infiltrates in alopecia areata are associated wit...
7728478 - Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft.
17725698 - Cosmetic improvement in various acute skin defects treated with tissue-engineered skin.
7964768 - Total knee arthroplasty in diabetic patients. comparison to a matched control group.
1928998 - Thermal laser assisted balloon angioplasty in lower extremity occlusive disease.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2007-11-12
Journal Detail:
Title:  Journal of the European Academy of Dermatology and Venereology : JEADV     Volume:  22     ISSN:  1468-3083     ISO Abbreviation:  J Eur Acad Dermatol Venereol     Publication Date:  2008 Mar 
Date Detail:
Created Date:  2008-02-13     Completed Date:  2008-05-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9216037     Medline TA:  J Eur Acad Dermatol Venereol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  320-3     Citation Subset:  IM    
Affiliation:
1st Academic Department of Dermatology, University of Athens Medical School, A Sygros Hospital, Athens, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adult
Alopecia Areata / drug therapy*,  immunology,  pathology
Cyclopropanes / administration & dosage*,  adverse effects
Dose-Response Relationship, Drug
Female
Hair / drug effects,  growth & development
Humans
Immunotherapy / methods*
Male
Middle Aged
Treatment Outcome
Chemical
Reg. No./Substance:
0/Cyclopropanes; 886-38-4/diphenylcyclopropenone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The use of topical calcineurin inhibitors in lupus erythematosus: an overview.
Next Document:  Radiographic assessment of the index to ring finger ratio (2D:4D) in adults.